Cargando…
Safety and efficacy of dual emission endoscopic laser treatment in patients with upper or lower gastrointestinal vascular lesions causing chronic anemia: results from the first multicenter cohort study
Objectives and study aims Recent pilot studies have assessed the feasibility of a novel 1.9-/1.5-μm dual emission endoscopic laser treatment ( (1.9-/1.5-μm) DEELT) for endoscopic hemostasis, ablation and resection. In this study, we investigated the safety and efficacy of (1.9-/1.5-μm) DEELT in pat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068277/ https://www.ncbi.nlm.nih.gov/pubmed/35528218 http://dx.doi.org/10.1055/a-1781-7066 |
Sumario: | Objectives and study aims Recent pilot studies have assessed the feasibility of a novel 1.9-/1.5-μm dual emission endoscopic laser treatment ( (1.9-/1.5-μm) DEELT) for endoscopic hemostasis, ablation and resection. In this study, we investigated the safety and efficacy of (1.9-/1.5-μm) DEELT in patients with chronic anemia due to gastrointestinal vascular lesions in a real-life multicenter cohort setting. Patients and methods Consecutive patients with moderate/severe iron-deficiency anemia undergoing (1.9-/1.5-μm) DEELT for upper and lower gastrointestinal bleeding due to vascular lesions were enrolled in three academic referral centers. Safety and successful ablation of vascular lesions were the primary outcomes. Long-term hemoglobin level, blood transfusion requirements, endoscopic severity scores of complex vascular disorders and technical lasing parameters were also assessed. Long-term hemoglobin variations have been further assessed, with repeated measure analysis of variance and univariate analyses. Results Fifty patients (median age 74; range 47 to 91 years) with gastric antral vascular ectasia (GAVE) (22), angioectasia (22) and radiation proctopathy (6) underwent 58 (1.9-/1.5-μm) DEELT between 2016 and 2020. All procedures were technically feasible leading to successful ablation of the targeted lesion/s, with no incident or adverse event potentially related to the (1.9-/1.5-μm) DEELT technique. Within a 6-month follow-up, hemoglobin values significantly rose (+ 1.77 at 1 month and + 1.70 g/dL at 6 months, P < 0.01), the blood supply requirement decreased (at least one transfusion in 32 versus 13 patients, P < 0.01), and GAVE lesions showed a clear endoscopic improvement (from 5 points to 1 points, P < 0.01). Conclusions The 1.9-/1.5-μm laser system is a safe and effective endoscopic tool for haemostatic ablation of bleeding vascular lesions within the gastrointestinal tract in tertiary referral centers. |
---|